Daniel Schneider
Chief Executive Officer chez PHOTOCURE ASA
Fortune : 508 182 $ au 31/03/2024
Profil
Daniel Schneider is currently the President & Chief Executive Officer at Photocure ASA since 2018.
Prior to this, he worked as the General Manager at Ablynx NV.
He holds an MBA from the University of Washington and an undergraduate degree from St. Louis University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
PHOTOCURE ASA
0,37% | 31/12/2022 | 99 689 ( 0,37% ) | 508 182 $ | 31/03/2024 |
Postes actifs de Daniel Schneider
| Sociétés | Poste | Début |
|---|---|---|
| PHOTOCURE ASA | Chief Executive Officer | 01/11/2018 |
Anciens postes connus de Daniel Schneider
| Sociétés | Poste | Fin |
|---|---|---|
| ABLYNX | Chief Executive Officer | - |
Formation de Daniel Schneider
| University of Washington | Masters Business Admin |
| St. Louis University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PHOTOCURE ASA | Health Technology |
| Entreprise privées | 1 |
|---|---|
Ablynx NV
 Ablynx NV BiotechnologyHealth Technology Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium. | Health Technology |
